Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA Mutation
HER2- Negative Breast Cancer
Hormone Receptor Positive Tumor
Breast Cancer
Metastatic Breast Cancer
Advanced Breast Cancer

Interventions

DRUG: RLY-2608
DRUG: Capivasertib
DRUG: Fulvestrant

Sponsor

Relay Therapeutics, Inc.